Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2017 by Janssen Research & Development, LLC
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:
NCT01517802
First received: January 23, 2012
Last updated: May 4, 2017
Last verified: May 2017
  Purpose
The purpose of this study is to collect follow-up safety data from participants in completed abiraterone acetate studies for a maximum duration of 6 years.

Condition Intervention Phase
Metastatic Castration-resistant Prostate Cancer
Metastatic Breast Cancer
Drug: Abiraterone acetate
Drug: Prednisone
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study

Resource links provided by NLM:


Further study details as provided by Janssen Research & Development, LLC:

Primary Outcome Measures:
  • The number of participants affected by a serious adverse event [ Time Frame: Up to 30 days after the last dose of study drug ]

Estimated Enrollment: 300
Actual Study Start Date: March 28, 2012
Estimated Study Completion Date: April 9, 2018
Estimated Primary Completion Date: April 9, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Abiraterone acetate
Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.
Drug: Abiraterone acetate
Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
Drug: Prednisone
Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily

Detailed Description:
This is a nonrandomized (individuals will not be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), long-term safety follow-up study of abiraterone acetate in approximately 300 patients from other completed abiraterone acetate clinical studies. Patients must have received at least 3 months of treatment with abiraterone acetate and a low-dose corticosteroid and, based on investigator assessment, may benefit from continued treatment. This study will consist of a screening period followed by open-label treatment of continued abiraterone acetate access. The patients will continue with the same abiraterone acetate and low-dose corticosteroid dosing regimen they were receiving in the previous abiraterone acetate clinical study until the investigator determines that the patient is no longer receiving benefit or the sponsor terminates the study. Patients can be withdrawn from the study if an alternative access (eg, patient-assistance program or commercial source of abiraterone acetate) is available and feasible. Each cycle of treatment will be 28 days. Investigators will monitor and assess the patients for response to treatment or progression according to routine practice or as clinically indicated to determine whether continued treatment with abiraterone acetate is warranted. No efficacy data are being collected. Safety will be monitored throughout the study for a maximum duration of 6 years. End-of-study assessments will be performed at least 30 days after the last dose of abiraterone or upon early withdrawal.
  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Currently participating in an abiraterone acetate clinical study considered complete and had received at least 3 months of treatment with abiraterone acetate tablets.

Exclusion Criteria:

  • Medical conditions that require hospitalization.
  • Any condition or situation which, in the opinion of the investigator, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01517802

Contacts
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: JNJ.CT@sylogent.com

  Hide Study Locations
Locations
United States, California
The Angeles Clinic and Research Institute Withdrawn
Los Angeles, California, United States, 90025
UCSF Helen Diller Family Comprehensive Cancer Center Withdrawn
San Francisco, California, United States, 94115
United States, Colorado
University of Colorado Cancer Center, Anschultz Cancer Pavilion Completed
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale Medical Group Withdrawn
New Haven, Connecticut, United States, 06520
United States, Georgia
Georgia Cancer Specialists Withdrawn
Atlanta, Georgia, United States, 30341
United States, Illinois
Rush University Medical Cntr Withdrawn
Chicago, Illinois, United States, 60612
United States, Louisiana
Hematology Oncology Specialists Completed
Marrero, Louisiana, United States, 70072
United States, Maryland
Sidney Kimmel Cancer Center at John Hopkins Withdrawn
Baltimore, Maryland, United States, 21205
United States, Massachusetts
Massachusetts General Hospital Cancer Center Completed
Boston, Massachusetts, United States, 02114
Dana Farber Cancer Centre Withdrawn
Boston, Massachusetts, United States, 02215
United States, Montana
Billings Clinic Withdrawn
Billings, Montana, United States, 59101
United States, Nebraska
GU Research Network Completed
Omaha, Nebraska, United States, 68130
United States, New York
North Shore Hem-onc Association Completed
East Setauket, New York, United States, 11733
Cornell Clinical Trials Unit - Weill Medical College of Cornell University Recruiting
New York, New York, United States, 10021
United States, Oregon
The Oregon Clinic Withdrawn
Portland, Oregon, United States, 97213
Oregon Health and Science University Withdrawn
Portland, Oregon, United States, 97239
United States, South Carolina
Carolina Urologic Research Center Completed
Myrtle Beach, South Carolina, United States, 29572
United States, Tennessee
Chattanooga Oncology & Hematology Associates, PC Completed
Chattanooga, Tennessee, United States, 37404
Sarah Cannon Research Institute Withdrawn
Nashville, Tennessee, United States, 37203
United States, Texas
Texas Oncology - Sammons Cancer Center Active, not recruiting
Dallas, Texas, United States, 75246
University of Texas MD Anderson Cancer Center Active, not recruiting
Houston, Texas, United States, 77030
Australia
St George Private Hospital Completed
Kogarah, Australia, 2217
Ashford Cancer Centre Recruiting
Kurralta Park, Australia, 5037
HOCA @ Mater Completed
South Brisbane, Australia, 4121
St John of God Hospital Subiaco Recruiting
Subiaco, Australia, 6008
Belgium
ZNA Middelheim Completed
Antwerpen, Belgium, 2020
Germany
Urologikum Hamburg Completed
Hamburg, Germany, 22399
Spain
Hospital Germans Trias y Pujol Active, not recruiting
Barcelona, Spain, 08916
Sweden
Akademiska Sjukhuset Recruiting
Uppsala, Sweden, 751 85
United Kingdom
Beatson West Of Scotland Cancer Centre Withdrawn
Glasgow, United Kingdom, G12 0YN
Newcastle-Upon-Tyne Hospitals NHS Foundation Trust Completed
Newcastle Upon Tyne, United Kingdom, NE7 7DN
East and North Hertfordshire NHS Trust Active, not recruiting
Northwood, United Kingdom, HA6 2RN
The Royal Marsden NHS Trust Sutton Active, not recruiting
Sutton, United Kingdom, SM2 5PT
Velindre NHS Trust Completed
Whitchurch, United Kingdom, CF14 2TL
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
  More Information

Additional Information:
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT01517802     History of Changes
Other Study ID Numbers: CR100797
212082PCR3010 ( Other Identifier: Janssen Research & Development, LLC )
2011-005243-28 ( EudraCT Number )
Study First Received: January 23, 2012
Last Updated: May 4, 2017

Keywords provided by Janssen Research & Development, LLC:
Metastatic castration-resistant prostate cancer
Metastatic breast cancer
Abiraterone acetate
Low-dose corticosteroid treatment
Long-term access

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Prednisone
Abiraterone Acetate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists
Cytochrome P-450 Enzyme Inhibitors

ClinicalTrials.gov processed this record on May 25, 2017